Who
Sarah Kathryn Rouan
Director
Company insider
Files Form 4 as: Director, Viking Therapeutics; Director, Navidea Biopharmaceuticals.
In numbers
- Trades disclosed
- 32
- Buys
- 3
- Sells
- 3
- Bought
- $65K
- Sold
- $2.3M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 2 Jan 2019
- Last trade
- 2 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,150 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,150 at $0.00 | filing |
| 31 Mar 2025filed 8 Apr 2025 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Bought | $30K1,240 at $24.15 | filing |
| 31 Mar 2025filed 2 Apr 2025 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Bought | $30K1,240 at $24.15 | filing |
| 2 Jan 2025filed 6 Jan 2025 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,800 at $0.00 | filing |
| 25 Oct 2024filed 25 Oct 2024 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
| 25 Oct 2024filed 25 Oct 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code M | $54K11,000 at $4.88 | filing |
| 25 Oct 2024filed 25 Oct 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $890K11,000 at $80.89 | filing |
| 8 Feb 2024filed 8 Feb 2024 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 8 Feb 2024filed 8 Feb 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code M | $208K25,000 at $8.32 | filing |
| 8 Feb 2024filed 8 Feb 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $701K25,000 at $28.05 | filing |
| 19 Jan 2024filed 19 Jan 2024 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 19 Jan 2024filed 19 Jan 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code M | $250K30,000 at $8.32 | filing |
| 19 Jan 2024filed 19 Jan 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $692K30,000 at $23.05 | filing |
| 2 Jan 2024filed 4 Jan 2024 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 3 Jan 2022filed 5 Jan 2022 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 30 Jun 2021filed 7 Jul 2021 | Navidea Biopharmaceuticals | SEC FORM 4 Code A | —4,892 at $0.00 | filing |
News
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 YearsVKTX · fool.com · 20 Oct 2026Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2VKTX · fool.com · 20 Oct 2026Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.VKTX · fool.com · 18 Oct 2026
0 headlines in the last 90 days name Sarah Kathryn Rouan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.